Thu, May 13, 2021
Wed, May 12, 2021
Tue, May 11, 2021

Sumant Kulkarni Maintained (ACAD) at Hold with Increased Target to $27 on, May 12th, 2021

Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $26 to $27 on, May 12th, 2021.

Sumant has made no other calls on ACAD in the last 4 months.



There are 11 other peers that have a rating on ACAD. Out of the 11 peers that are also analyzing ACAD, 8 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Fein of "HC Wainwright & Co." Downgraded from Strong Buy to Hold and Decreased Target to $18 on, Wednesday, April 7th, 2021
  • Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $21 on, Tuesday, April 6th, 2021
  • Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Tuesday, April 6th, 2021
  • Vamil Divan of "Mizuho" Downgraded from Strong Buy to Hold and Held Target at $25 on, Tuesday, April 6th, 2021
  • Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold on, Wednesday, March 10th, 2021
  • Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $35 on, Tuesday, March 9th, 2021
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $27 on, Tuesday, March 9th, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Tuesday, March 9th, 2021


These are the ratings of the 3 analyists that currently disagree with Sumant


  • Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Increased Target to $29 on, Thursday, May 6th, 2021
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, April 5th, 2021
  • Danielle Brill of "Raymond James" Downgraded from Strong Buy to Buy and Decreased Target to $35 on, Tuesday, March 9th, 2021